Royce & Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-13,821
Closed -$51.6K 917
2024
Q3
$51.6K Hold
13,821
﹤0.01% 857
2024
Q2
$77.4K Hold
13,821
﹤0.01% 859
2024
Q1
$72.4K Buy
+13,821
New +$75.9K ﹤0.01% 866
2023
Q4
Sell
-50,548
Closed -$797K 951
2023
Q3
$797K Sell
50,548
-8,666
-15% -$156K 0.01% 770
2023
Q2
$1.15M Buy
59,214
+11,582
+24% +$275K 0.01% 742
2023
Q1
$1.35M Buy
47,632
+12,437
+35% +$369K 0.01% 730
2022
Q4
$1.03M Buy
35,195
+11,320
+47% +$360K 0.01% 751
2022
Q3
$631K Sell
23,875
-6,550
-22% -$240K 0.01% 792
2022
Q2
$1.35M Sell
30,425
-6,197
-17% -$285K 0.01% 709
2022
Q1
$1.81M Buy
36,622
+17,978
+96% +$863K 0.02% 728
2021
Q4
$949K Buy
18,644
+1,964
+12% +$102K 0.01% 816
2021
Q3
$930K Buy
16,680
+882
+6% +$43.4K 0.01% 827
2021
Q2
$676K Buy
15,798
+742
+5% +$30.6K ﹤0.01% 889
2021
Q1
$628K Buy
15,056
+2,402
+19% +$112K ﹤0.01% 899
2020
Q4
$589K Sell
12,654
-65
-0.5% -$3.04K ﹤0.01% 869
2020
Q3
$540K Sell
12,719
-25,046
-66% -$1.1M 0.01% 853
2020
Q2
$1.81M Sell
37,765
-13,882
-27% -$693K 0.02% 685
2020
Q1
$2.38M Buy
51,647
+1,661
+3% +$83.3K 0.03% 556
2019
Q4
$3M Sell
49,986
-8,781
-15% -$524K 0.03% 611
2019
Q3
$3.32M Sell
58,767
-8,866
-13% -$499K 0.03% 584
2019
Q2
$3.77M Buy
67,633
+3,150
+5% +$164K 0.03% 562
2019
Q1
$3.26M Buy
64,483
+27,344
+74% +$1.22M 0.03% 605
2018
Q4
$1.5M Sell
37,139
-3,894
-9% -$201K 0.01% 801
2018
Q3
$2.85M Buy
41,033
+758
+2% +$57.5K 0.02% 747
2018
Q2
$3.05M Sell
40,275
-29,768
-42% -$1.87M 0.02% 734
2018
Q1
$3.69M Sell
70,043
-21,291
-23% -$1.24M 0.03% 660
2017
Q4
$4.88M Buy
91,334
+23,418
+34% +$1.3M 0.03% 594
2017
Q3
$4.05M Buy
+67,916
New +$4.11M 0.03% 640

Other funds holding EGRX